Safety of transtuzumab deruxtecan in the treatment for late-stage breast cancer after multimodal therapies fail
Yang Ai-ling
Bai Li-xiao
Li Jia-yi
Su Xuan
Wang Yan
Abstract：Objective To analyze the adverse reactions and the life quality of patients with advanced breast cancer treated with a new type of anti-HER2 drugs,transtuzumab deruxtecan(ENHERTU,DS-8201).Methods 31 patients with breast cancer who had been treated with DS-8201 in the Fifth Medical Center of Chinese PLA General Hospital from January 2020 to January 2023 were retrospectively analyzed.Results All 31 patients experienced varying degrees of adverse reactions,including 7 cases of grade Ⅲ hematological toxicity and 3 cases of grade Ⅳ hematological toxicity.Most adverse reactions were loss of appetite and nausea,which occurred on the second day after medication,were the severest on the fifth day and disappeared on the tenth day.The physiological status,social/family status,emotional state,functional status and additional concern of patients as well as total score in the functional assessment of cancer therapy-breast(FACT-B)were higher than before administration,and the differences were statistically significant(P<0.05).Conclusion The use of DS-8201 had a positive impact on the life quality of patients,but there were also some adverse reactions.The monitoring of adverse reactions during medication should be strengthened in clinical practices.
Keywords：Breast cancerAntibody-drug conjugateTranstuzumab deruxtecanAdverse drug reaction
Publication Date：2024-02-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 21-24 )